Brief: Assembly Biosciences Announces Promising Interim Results From Two Clinical Trials Evaluating Next-Generation Core Inhibitor Candidates
19/12/2022 13:06
Dec 19 (Reuters) - Assembly Biosciences Inc ASMB.O :
* ASSEMBLY BIOSCIENCES ANNOUNCES PROMISING INTERIM RESULTS
FROM
TWO CLINICAL TRIALS EVALUATING HIGHLY POTENT NEXT-GENERATION
CORE INHIBITOR CANDIDATES ABI-H3733 AND ABI-4334
* INITIAL ABI-4334 PHASE 1A SINGLE-DOSE 30 MG COHORT
DEMONSTRATED
PHARMACOKINETIC PROFILE SUPPORTIVE OF ONCE-DAILY ORAL DOSING
* PROVIDES EARLY INDICATION THAT ABI-4334'S VERY HIGH
POTENCY SEEN
PRECLINICALLY CAN BE ACCESSED CLINICALLY
* NO SERIOUS ADVERSE EVENTS OR SIGNIFICANT LABORATORY
ABNORMALITIES INCLUDING ALANINE AMINOTRANSFERASE ELEVATION WERE
OBSERVED
Source text for Eikon: ID:nGNX7QZrv3
Further company coverage: ASMB.O
((Reuters.Briefs@thomsonreuters.com))